Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its Second Quarter 2025 financial results announcement for July 30, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. Investors can join via phone using specific dial-in numbers or access the webcast through TransMedics' investor relations website.
TransMedics (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:00 a.m. EST. Both presentations will be available via webcast on TransMedics' investor relations website.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Investors can participate by dialing (844) 676-6010 (domestic) or (412) 634-6944 (international). A live and archived webcast will be available on the company's investor relations website.
TransMedics Group (TMDX) announced the granting of inducement awards to three new employees on March 28, 2025. The compensation package includes:
- 1,570 non-qualified stock options with an exercise price of $68.58 per share
- 1,043 restricted stock units (RSUs)
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Inducement Plan.
TransMedics (TMDX) reported strong financial results for Q4 and full year 2024. The company achieved total revenue of $121.6 million in Q4 2024, up 50% year-over-year, and full-year revenue of $441.5 million, representing an 83% increase from 2023.
Key highlights include net income of $6.9 million ($0.19 per diluted share) in Q4 and $35.5 million ($1.01 per diluted share) for the full year 2024. The company completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2023, and achieved a 20.9% overall OCS market share across all organs.
For 2025, TransMedics projects revenue between $530-552 million, representing 20-25% growth. The company maintained a strong cash position of $336.7 million as of December 31, 2024.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced its participation in two major investor conferences in March 2025. The company will present at:
1. The TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 11:50 a.m. EST
2. The Oppenheimer 35th Annual Healthcare MedTech & Services Conference virtually on March 17, 2025, at 9:20 a.m. EST
Interested parties can access live and archived webcasts of both presentations through the 'Investors' section of TransMedics' website. The company's standard investor presentation will also be available through the same platform.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the results.
Investors can participate in the conference call by dialing (844) 481-2832 (domestic) or (412) 317-1852 (international). A live and archived webcast will be available on the company's investor relations website.
TransMedics Group (TMDX) has announced the granting of inducement awards to three new employees on January 28, 2025. The compensation package includes:
- 34,884 non-qualified stock options with an exercise price of $67.03 (closing price on grant date)
- 23,192 restricted stock units (RSUs)
The stock options will vest 25% after one year, with the remainder vesting monthly over three years. They have a 10-year term. The RSUs will vest 25% annually over four years. Both grants are subject to continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group Inducement Plan.